Hepatotoxic adverse drug reactions are associated with significant morbidity and mortality and are the leading cause of postmarketing regulatory action in the United States. They are classified as Type A (intrinsic) or Type B (idiosyncratic). Type A are predictable, dose-related toxicities, often identified in preclinical or clinical trials, and usually occur in overdose settings or with pre-existing hepatic impairment. Type B are not clearly related to increasing dose and are associated with drug-specific and patient-specific characteristics and environmental risks. Rare Type B reactions are often identified postmarketing. Identification and management, including electronic resources, has evolved.
CITATION STYLE
Iasella, C. J., Johnson, H. J., & Dunn, M. A. (2017, February 1). Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Clinics in Liver Disease. W.B. Saunders. https://doi.org/10.1016/j.cld.2016.08.005
Mendeley helps you to discover research relevant for your work.